免疫刺激性CELMoD联合方案克服高肿瘤负荷所致T细胞衔接器耐药
研究在免疫功能完整的IMiD敏感Vk*MYChCRBN小鼠多发性骨髓瘤模型中优化BCMA-TCE联合策略。抗PD1联合泊马度胺可提高缓解率但增加致死性细胞因子释放综合征风险;伊贝度胺与地塞米松预处理使高肿瘤负荷对象缓解率达100%并延长生存,且细胞因子释放综合征风险降低。
要点
- 高肿瘤负荷是多发性骨髓瘤患者对BCMA-TCE原发耐药的驱动因素。
- 抗PD1联合泊马度胺提高缓解率但增加致死性细胞因子释放综合征风险。
- 地塞米松与伊贝度胺预处理后序贯TCE使高肿瘤负荷对象缓解率达100%。
核心结论
- 在地塞米松和伊贝度胺治疗后给予TCE,可获得更深、更持久的缓解,并降低细胞因子释放综合征风险。
研究设计与样本
- 研究采用免疫功能完整、对IMiD敏感的Vk*MYChCRBN小鼠多发性骨髓瘤模型,优化克服BCMA-TCE原发耐药的联合策略。
主要发现
- 抗PD1联合泊马度胺减少高肿瘤负荷下TCE引起的T细胞耗竭,提高T细胞活化程度并显著改善缓解率,但增加致死性细胞因子释放综合征风险。
- 伊贝度胺与地塞米松预处理重塑骨髓T细胞区室、促进初始T细胞浸润,使高肿瘤负荷对象缓解率达100%并获最长生存。
- 该联合方案伴随更有利的T细胞特征,调节性T细胞扩增和耗竭均有限。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bispecific T-cell engagers (TCEs) targeting B-cell maturation antigen (BCMA) and CD3, induce deep hematologic responses in ∼60% of heavily pretreated patients with multiple myeloma (MM). We and others found that high tumor burden leads to resistance to TCE and novel strategies are urgently needed to improve responses in this setting. Ikaros degraders, including immunomodulatory drugs (IMiDs) and cereblon E3 ligase modulatory drugs (CELMoDs), represent logical partners for TCEs due to their direct anti-MM effects and additional immune-stimulatory activity; however, it is unclear how to optimally combine them with TCEs. Taking advantage of the immunocompetent IMiD-sensitive Vk∗MYChCRBN murine model of MM, we optimized strategies to overcome primary resistance to BCMA-TCEs and achieve sustained remission, while maintaining a manageable safety profile. The addition of anti-programmed cell death protein 1 (PD1) and pomalidomide reduced the T-cell exhaustion that occurs in response to TCEs in high tumor burden settings. This allowed for a higher degree of T-cell activation and significant improvement in response rates but also increased risk of lethal cytokine release syndrome (CRS). To moderate the response and prevent CRS, we evaluated Ikaros degraders and dexamethasone (DEX) with step-up-dosed TCEs. Pretreatment with iberdomide and DEX reshaped the bone marrow T-cell compartment, promoted infiltration of naïve T cells, and generated 100% response rates and the longest survival in subjects with high tumor burden. This was accompanied by more favorable T-cell profiling, with limited expansion of regulatory T cells and exhaustion. Overall, administering a TCE after DEX and iberdomide treatments provided deeper and more durable responses with a reduced risk of CRS.
引用
- Meermeier EW, Pfeffer K, Stein CK, et al. An immunostimulatory CELMoD combination overcomes resistance to T-cell engagers caused by a high multiple myeloma burden. Blood. 2025. PMID: 40864972. doi:10.1182/blood.2025029215
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。